GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:

Size: px
Start display at page:

Download "GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:"

Transcription

1 GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose combination of abacavir/dolutegravir/lamivudine from current antiretroviral regimen compared with continuation of the current antiretroviral regimen in HIV-1 infected adults who are virologically suppressed, final results. Rationale: The purpose of Study was to compare switching from current antiretroviral regimen to administered once daily in the treatment of human immunodeficiency virus type 1 (HIV-1) infected adults who are virologically suppressed. : IIIb Study Period: 06-May-2014 to 29-Dec-2015 (week 48 and continuation phase) Study Design: Study is a 48-week, IIIb, randomly assigned, open-label, active-controlled, multicenter, parallel group, non-inferiority study. The primary analysis took place after the last subject completed the Week 24 visit. Additional analyses were conducted after the last subject completed the Week 48 visit and after the last subject withdrew from the study or transitioned to commercial supplies (i.e., completes the Continuation ). The study included a Screening Period (14 to 28 days), a Randomized/ (24 weeks), a (24 weeks), and a Continuation. Centers: This study was conducted at 96 investigational centers (defined as having enrolled one or more subjects): 85 centers in the United States (4 of the 85 were in Puerto Rico) and 11 centers in Canada. Indication: HIV-1 infected adults who are virologically suppressed Treatment: Eligible subjects were randomly assigned 1:1 to continue their current regimen or were switched to once daily for 24 weeks. At Week 24, individuals originally randomly assigned to continue their current regimen switched to and were followed for an additional 24 weeks. Individuals initially randomly assigned to continued on that treatment arm for an additional 24 weeks. Subject randomization was stratified by current antiretroviral therapy () third-agent class (protease inhibitor [PI], non-nucleoside nucleoside reverse transcriptase inhibitor [NNRTI], or integrase inhibitor [INI]). All subjects who successfully completed a total of 48 weeks of treatment continued to have access to in the Continuation until it was either locally approved and commercially available, the subject no longer derived clinical benefit, the subject met a protocoldefined reason for discontinuation, or development of was terminated. Objective: The primary objective was to demonstrate the non-inferior antiviral activity of administered once daily compared with continuation of current antiretroviral regimen over 24 weeks in HIV-1 infected adult subjects with virologic suppression. Primary Outcome (Endpoint)/Efficacy: The primary efficacy endpoint for this study was the proportion of subjects with plasma HIV-1 RNA <50 c/ml at Week 24 using the Snapshot (Missing, Switch, or Discontinuation = Failure [MSDF]) algorithm for the Intent-to-Treat Exposed (ITT-E) Population. Secondary Outcome (Endpoints)/Efficacy: The following were the secondary efficacy endpoints for this study: Change from Baseline in CD4+ cell counts at Week 24 Tertiary Outcome (Endpoints)/Efficacy: The following were the tertiary efficacy endpoints for this study: Proportion of subjects with plasma HIV-1 RNA <50 c/ml at Week 48; Change from Baseline in CD4+ cell counts at Week 48; Incidence of disease progression (HIV-associated conditions, AIDS, and death) over time. Statistical Methods: The primary endpoint was the proportion of subjects with plasma HIV-1 RNA <50 c/ml at Week 24 (using the FDA Snapshot analysis). Non-inferiority was based on the lower bound of a 2-sided 95% confidence interval (CI) for the difference in response rates between the 2 treatment arms being greater than -10%. The power of this study was based on a response rate of 85%. Assuming this rate of response at Week 24 for both arms, the study required 269 evaluable subjects per treatment arm to have 90% power with a 10% non-inferiority margin and a 1-sided 2.5% significance level. The primary efficacy analyses were conducted based on the ITT-E Population, which consisted of all subjects who were randomized to and received at least 1 dose of IP or were randomized to remain on current regimen and continued in the study past Day 1. Subjects were assessed according to their randomized treatment, 1

2 regardless of the treatment they received. The PP Population consisted of all subjects who were in the ITT-E Population with the exception of those with a significant protocol deviation before Week 24. The PP Population was used for supporting sensitivity analyses of the primary endpoint analysis. No PP Population was defined for the. The ITT-E Population and Safety Population were the primary populations used for the Week 48 efficacy and safety analyses. These populations were defined as follows: All subjects originally randomized to who received at least 1 dose of study treatment; Subjects originally randomized to continue on their current regimen and who completed the and received at least 1 dose of upon switching at Week 24. Subjects were not included in summaries/analyses of data if they discontinued treatment prior to Week 24 while on their current regimen. For the -ITT-E Population, subjects were assessed according to their randomized treatment, regardless of the treatment they received unlike the Safety Population. At Week 48, tolerability and long-term safety over time following switch to was assessed by the incidence of AEs and SAEs and graded laboratory toxicities, as well as summaries of laboratory tests and vital sign measurements. For the analyses of the health outcome endpoints, change from Baseline in the HIV treatment satisfaction questionnaire (TSQ) (2006) of total scores, general satisfaction/clinical subscale scores, and lifestyle/ease subscale scores at Week 48 was measured. Any incidence of treatment-emergent genotypic and phenotypic resistance to NRTIs, NNRTIs, and INIs was summarized by treatment arm at Week 48. Two post hoc analyses were performed: A post hoc sensitivity analysis was performed to include subject data for those individuals who were included in the ITT-E Population, but whose week 48 visit was outside of the allowed visit window. This affected 16 subjects of whom 10 were taking commercial Triumeq at week 48; thus, for 10 subjects, their HIV-RNA results at week 48 were considered on treatment. This analysis is considered to be the main analysis at Week 48 and represents the clinical reality of the study (original ITT-E not presented here). A second post hoc sensitivity analysis was performed to exclude n=20 subjects randomized, where the Sponsor became aware of GCP noncompliance issues in another ViiV Healthcare-sponsored study. Study Population: The following were the main inclusion criteria: HIV-1 infected men or women 18 years of age; two consecutive plasma HIV-1 RNA measurements <50 c/ml within the last year and plasma HIV-1 RNA <50 c/ml at Screening; subject on current regimen (whether first or second line combination [c]) for at least 6 months prior to Screening; subject with plasma HIV-1 RNA <50 c/ml within 6 months of start of initial c regimen and no plasma HIV-1 RNA >200 c/ml following initial suppression; subject was negative for the human leukocyte antigen B*5701 allele. The following were the main exclusion criteria: any evidence of an active (Centers for Disease Control and Prevention Category C) disease (exceptions included cutaneous Kaposi s sarcoma not requiring systemic therapy and historic CD4+ cell counts of <200 cells/mm 3 ); subjects with any degree of hepatic impairment; subjects positive for hepatitis B virus surface antigen at Screening or with an anticipated need for hepatitis C virus therapy during the study; subjects who had a history of use of only mono or dual nucleoside reverse transcriptase inhibitor (NRTI) therapy prior to starting c; subjects who used etravirine at time of switch; subjects who used DTG at time of switch; subjects with evidence of primary viral resistance based on the presence of any resistance associated major PI, NRTI, NNRTI, or INI mutation in any prior resistance genotype assay result; creatinine clearance of <50 ml/min/1.73m 2 using Modification of Diet in Renal Disease. The primary endpoint of this study was reported at Week 24. The Week 24 results are presented here for 2

3 completeness, along with the Week 48 results. Randomization/ ITT-E Population ITT-E Population Number of Subjects: Planned, N Randomised, N Randomised and Exposed, N Completed, 239 (87) 244 (88) 230 (84) 230 (94) Premature Withdrawal: 36 (13) 33 (12) 45 (16) 14 (6) Withdrawn due to AE, 10 (4) 0 10 (4) 4 (2) Withdrawn for Other Reasons, 26 (9) 33 (12) 35 (13) 10 (4) Demographics N Females: Males 38:237 40:238 38:237 32:212 Age, years ( 45 (22-74) 47 (22-80) 45 (22-74) 47 (23-80) White, 177 (64) 184 (66) 178 (65) 165 (68) Baseline CD4+ (cells/mm 3 ), < (30) 91 (33) 83 (30) 66 (27) (70) 186 (67) 192 (70) 178 (73) Time Since First Until Screening (months) Primary Efficacy Results Proportion of Subjects With Plasma HIV-1 RNA <50 c/ml at Week 24/48 Snapshot Analysis n(%) Timepoint Week 24 Week 48 Virologic Success 233/275 (85) 245/278 (88) 227/275 (83)* 224/244 (92)* Adjusted difference (95% CI) -3.4, (-9.1, 2.4) Secondary Outcome Results: *Commercial IP sensitivity analysis is considered the primary analysis at Week 48 (n=10 subjects taking commercial at Week 48; results considered on-treatment) N=278 * Change From Baseline in CD4+ Cell Count (cells/mm 3 ) Baseline ( n=275;, n=278; ES n=275; LS n=244) Week 24 ( n=238;, n=248; ES n=238) (460.0, 812.0) 50.0 (-48.0, 130.0) (444.0, 794.0) 11.0 (-60.0, 103.5) (460.0, 812.0) 50.0 (-48.0, 130.0) (468.5, 810.0) 3

4 Week 48 (ES n=226; LS n=223) *Baseline is the last assessment prior to switch (-45.0, 142.0) 34.0 (-46.0, 131.0) Virology: No subjects met the confirmed virologic withdrawal criteria; hence, no resistance was identified throughout the study Safety Results: For the, on-treatment AEs and SAEs for both the and treatment groups were defined as events with onset after the start date of study drug (Day 1), but not after the Week 24 visit. For the, for the group on-treatment AEs and SAEs were defined as events with onset after the start date of study drug (Day 1), but not after the Week 48 visit. For the Late Switch group on-treatment AEs and SAEs were defined as events with onset after the date of the Week 24 visit, but not after the Week 48 visit. The Most Frequent (>=5% in any treatment group) On-treatment Adverse Events in the Randomized/Early and Late Switch [sorted by Frequency] Randomization/ Safety Population* N=276 N=277 Safety Population Subjects with any AE 183 (66) 129 (47) 206 (75) 146 (60) Nausea 27 (10) 3 (1) 28 (10) 15 (6) Diarrhoea 17 (6) 4 (1) 20 (7) 9 (4) Upper respiratory tract infection 21 (8) 20 (7) 35 (13) 22 (9) Fatigue 19 (7) 3 (1) 22 (8) 6 (2) Cough 14 (5) 8 (3) 17 (6) 6 (2) Headache 13 (5) 4 (1) 17 (6) 6 (2) Nasopharyngitis 10 (4) 6 (2) 13 (5) 6 (2) Insomnia 10 (4) 1 (<1) 14 (5) 9 (4) * One subject was entered into the study while receiving DTG + ABC/3TC and was randomly assigned to continue c. This subject therefore is counted in the c group in the ITT-E Population, but in the group in the Safety Population. Serious Adverse Events - On-treatment Randomized/Early and [n considered by the investigator to be related to study medication] N=276 System Organ Class Preferred Term Subjects With any SAE, Included both fatal and nonfatal events 6 (2) [0] 5 (2) [0] 9 (3%) [0] 6 (2%) [0] Cardiac disorders Cardiac failure congestive 1 (<1) [0] 0 1 (<1) [0] 0 Myocardial infarction (<1%) [0] Infections and infestations Cellulitis 1 (<1) [0] 1 (<1) [0] 1 (<1) [0] 0 Diverticulitis (<1) [0] Gastroenteritis (<1) [0] 0 Meningitis bacterial 0 1 (<1) [0] 0 0 Pneumonia bacterial (<1) [0] 0 Pyelonephritis (<1) [0] 0 Subcutaneous abscess (<1) [0] 4

5 Musculoskeletal and connective tissue disorders Intervertebral disc degeneration 0 1 (<1) [0] 0 0 Nervous system disorders Cerebrovascular accident 1 (<1) [0] 0 1 (<1) [0] 0 Hemiparesis 1 (<1) [0] Hypoaesthesia 1 (<1) [0] Speech disorder 1 (<1) [0] Psychiatric disorders Suicide attempt 1 (<1) [0] 0 1 (<1) [0] 0 Renal and urinary disorders Nephrolithiasis 0 1 (<1) [0] 0 0 Social circumstances Homicide 1 (<1) [0] 0 1 (<1) [0] 0 Vascular disorders Aortic thrombosis 0 1 (<1) [0] 0 0 Hypertension (<1) [0] 0 Respiratory, thoracic and mediastinal disorders Asthma (<1) [0] 0 Pulmonary embolism (<1) [0] General disorders and administration site conditions Non-cardiac chest pain (<1) [0] 0 Injury, poisoning and procedural complications Femur fracture (<1) [0] Investigations Alanine aminotransferase increased (<1) [0] Subjects With Fatal SAEs, Homicide 1 (<1) [0] 0 1 (<1) [0] 0 Myocardial infarction (<1) [0] Conclusion: In virologically suppressed patients, switching to once daily was non-inferior to continuing c, with no evidence of virologic failure or treatment emergent resistance through 48 weeks. Early switch subjects also maintained virologic suppression from Week 24 through Week 48. There were fewer withdrawals due to AEs in the vs. arm. The safety profile of in STRIIVING is consistent with current labeling for. 5

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects

SINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,

More information

VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects

VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ABC/3TC/ZDV ABC PBO/3TC/ZDV

ABC/3TC/ZDV ABC PBO/3TC/ZDV The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results

Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy

More information

Introduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.

Introduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2. Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in

More information

GlaxoSmithKline, London, United Kingdom; 11 ViiV Healthcare, London, United Kingdom

GlaxoSmithKline, London, United Kingdom; 11 ViiV Healthcare, London, United Kingdom Switching to Dolutegravir /Abacavir/Lamivudine Fixed Dose Combination ( FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression at 48 Weeks J Lake, 1 B Trottier, 2 J Garcia-Diaz, 3 H Edelstein,

More information

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for

More information

Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016

Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016 Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Purpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation

Purpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation ANDREW LEE Purpose Methods Demographics of patients in the study Outcome Efficacy Adverse Event Limitation Dolutegravir Integrase inhibitor Plasma half life 14hours Tivicay FDA (US)- 13 August 2013 50mg

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive

More information

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Study Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)

Study Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study) Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Uveitis Approved Indication Investigational Study Number CC2302 (core study) and CC2302E1

More information

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1 Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,

More information

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study

More information

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

VIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects

VIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects VIKING STUDIES Efficacy and safety of dolutegravir treatment-experienced subjects (DTG) in UK/DLG/0083/14e(2) Date of preparation: February 2017 Prescribing information is available at the end of this

More information

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1 Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy

More information

SECONDARY OBJECTIVES:

SECONDARY OBJECTIVES: Study No.: 112 419 Title: Retrospective study using the NADIS database of the reasons for discontinuing the Abacavir-Lamivudine combination in HIV-infected patients treated by an antiretroviral regimen

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

CL Vavro, 1 J Huang, 2 C Avatapally, 1 S Min, 1 and M Ait-Khaled 3. GlaxoSmithKline: 1 Research Triangle Park,NC, USA; 2 Toronto, ON, Canada; 3

CL Vavro, 1 J Huang, 2 C Avatapally, 1 S Min, 1 and M Ait-Khaled 3. GlaxoSmithKline: 1 Research Triangle Park,NC, USA; 2 Toronto, ON, Canada; 3 Durable Efficacy and Limited Integrase Resistance Evolution in Subjects Receiving Dolutegravir After Failing Prior Integrase Inhibitor (INI) Regimens: Week 48 Results from VIKING-3 CL Vavro, 1 J Huang,

More information

Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study

Study No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory

More information

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

IAC Analyst Presentation

IAC Analyst Presentation IAC Analyst Presentation David Redfern Chairman, ViiV Healthcare Chief Strategy Officer, GSK July 27, 2012 1 ViiV Healthcare Dr Dominique Limet CEO, ViiV Healthcare July 27, 2012 2 Equity split of 85%

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Synopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)

Synopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0) SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant

More information

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI) PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

FLAMINGO 96-WEEK PRESENTATION DATA

FLAMINGO 96-WEEK PRESENTATION DATA FLAMINGO 96-WEEK PRESENTATION DATA Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14j(3) Date of preparation: February 2017 Prescribing information is available at the

More information

Sponsor. Generic Drug Name. Trial Indications. Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Reason for Termination

Sponsor. Generic Drug Name. Trial Indications. Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Reason for Termination Sponsor Alcon Research, Ltd. Generic Drug Name Travoprost/timolol maleate Trial Indications Open-angle glaucoma or ocular hypertension Protocol Number C-09-007 Protocol Title An Evaluation of Patient Reported

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)

Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

FLAMINGO 96-WEEK PRESENTATION DATA

FLAMINGO 96-WEEK PRESENTATION DATA FLAMINGO 96-WEEK PRESENTATION DATA Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14j(4) Date of preparation: August 2017 Prescribing information is available at the

More information

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ViiV Healthcare Investor and Analyst Update 24 July 2018

ViiV Healthcare Investor and Analyst Update 24 July 2018 ViiV Healthcare Investor and Analyst Update 24 July 2018 Cautionary statement regarding forward looking statements This presentation may contain forward-looking statements. Forward-looking statements give

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium darunavir 300mg tablets (Prezista ) No. (378/07) Tibotec (a division of Janssen-Cilag Ltd) 4 May 2007 The Scottish Medicines Consortium has completed its assessment of the

More information

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Search for studies: ClinicalTrials.gov Identifier: NCT

Search for studies: ClinicalTrials.gov Identifier: NCT ClinicalTrials.gov A service of the U.S. National Institutes of Health Search for studies: Example. "Heart attack" AND "Los Angeles" Advanced Search Help Studies by Topic Glossary Find Studies About Clinical

More information

Nilotinib AEs (adverse events) in CML population:

Nilotinib AEs (adverse events) in CML population: Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Clinical Trial Results Summary Study EN3409-BUP-305

Clinical Trial Results Summary Study EN3409-BUP-305 Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin

More information

Clinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia

Clinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New

More information

1.0 Abstract. Title. Keywords

1.0 Abstract. Title. Keywords 1.0 Abstract Title Real World Evidence of the Effectiveness of Paritaprevir/r Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients with Chronic Hepatitis C - An Observational Study in Austria (REAL) Keywords

More information

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers). Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,

More information

SYNOPSIS. Clinical Study Report IM Double-blind Period

SYNOPSIS. Clinical Study Report IM Double-blind Period Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority

More information

CROI 2017 Review: Novel ART Strategies

CROI 2017 Review: Novel ART Strategies Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir

The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects with Virologic Suppression

More information

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

GS-1489: STUDY DESIGN

GS-1489: STUDY DESIGN A PHASE 3 RANDOMIZED CONTROLLED CLINICAL TRIAL OF BICTEGRAVIR IN A FIXED DOSE COMBINATION,, VS ABC/DTG/3TC IN TREATMENT-NAÏVE ADULTS AT WEEK 48 J. Gallant, A. Lazzarin, A. Mills, C. Orkin, D. Podzamczer,

More information

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating

More information

Sponsor / Company: Sanofi Drug substance(s): AMARYL M (1/250 mg) / HOE490

Sponsor / Company: Sanofi Drug substance(s): AMARYL M (1/250 mg) / HOE490 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Final Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110

Final Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110 BMS-475 AI463 Name of Sponsor/Company: Bristol-Myers Squibb Individual Study Table Referring to the Dossier For National Authority Use Only) Name of Finished Product: Baraclude Name of Active Ingredient:

More information

ART Treatment. ART Treatment

ART Treatment. ART Treatment Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r

More information

Reports of efficacy and safety studies of primary immunodeficiency

Reports of efficacy and safety studies of primary immunodeficiency 2. SYNOPSIS TITLE OF STUDY: Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of IGIV3I GRIFOLS [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency

More information

Analysis of immunogenicity

Analysis of immunogenicity The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0162. Referring to Part of Dossier: Volume: Page:

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0162. Referring to Part of Dossier: Volume: Page: 2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-

More information

Supplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:

Supplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if: Supplemental Appendix 1. Protocol Definition of Sustained Virologic Response A patient has a sustained virologic response if: 1. The patient is a responder at the end of treatment and all subsequent planned

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Dolutegravir-Rilpivirine (Juluca)

Dolutegravir-Rilpivirine (Juluca) Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL

More information

Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir

Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide () Bryan Baugh 1, Erika Van Landuyt 2, Simon Vanveggel 2, Herta

More information

Clinical Trial Synopsis TL-OPI-525, NCT#

Clinical Trial Synopsis TL-OPI-525, NCT# Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS

More information

Summary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ

Summary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar

More information

GSK Medicine: Study Number:

GSK Medicine: Study Number: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Abstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo

Abstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0144. Referring to Part of Dossier: Volume: Page:

ABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0144. Referring to Part of Dossier: Volume: Page: 2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-

More information

Bristol-Myers Squibb

Bristol-Myers Squibb A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone

DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites

ClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

Clinical Trial Synopsis

Clinical Trial Synopsis Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)

Sponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and

More information